News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

April

21

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

Evaluation results indicate nVNS therapy may potentially improve the course of patients’ COVID-19 symptoms...

19

gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program

If initial findings are confirmed, program calls for field-ready gammaCore™ nVNS devices in 2H-2023 ROCKAWAY,...

12

TriSalus Life Sciences Opens Its First Research Laboratory on Lifespan Health System’s Campus

Immunotherapeutic collaboration will advance efforts to develop new treatment options for patients with liver...

12

electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance

Record revenue from product sales will be approximately $1.9M; approximately 60% growth over first quarter 2021...

5

ATEC to Host Investor Day on May 25, 2022

In-person and virtual event will take place 9am – 12pm PT CARLSBAD, Calif.–(BUSINESS WIRE)–...

5

electroCore Announces Exclusive License Agreement with Teijin for Japan Territory

Upon favorable regulatory and payor coverage decisions in Japan, the parties will enter into an...

30

Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems

AVISE® Lupus and AVISE® CTD tests included in agreement SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE)...

22

Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives

New partnership will bring total patients with in-network testing benefit to more than 90...

22

Neurolens Partners With The University Of Montreal’s Clinique Universitaire De La Vision

Joint projects will fuel Neurolens clinical foundation and future product innovations Coppell, Texas, March 22,...

22

Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results

Six Quarterly Records: AVISE® CTD Volume, Testing Revenue, Testing Gross Margin, Testing Gross Margin...

16

Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board

SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions,...

10

electroCore Announces Fourth Quarter and Full Year 2021 Financial Results

Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020...